
Tempus AI
Two engines: (1) Genomics/Diagnostics - reimbursed clinical sequencing tests (oncology NGS, hereditary, MRD, cardiology); (2) Data & Applications - licensing de-identified multimodal oncology data and AI/insights products to pharma and biotech. Razor/razorblade: tests generate the proprietary data asset that the higher-margin data business monetizes.
- 2026-08-04This market capitalisation previously read ~$10.82B (as of 2026-07-06). Restated to ~$8.31B on this refresh, roughly 23% lower.
- 2026-08-04This share price previously read ~$60.52 (as of 2026-07-06). Restated to $46.05 on this refresh, roughly 24% lower.
Sources — 12 figures with citations
- Q2 2026 income statementfiled2026-06-30 (released 2026-07-30)Total net revenue $382,486k (Diagnostics $289,333k, Data & applications $93,153k) vs $314,635k a year ago; gross profit $246,498k; loss from operations $(75,913)k vs $(61,774)k; net income $5,642k vs $(42,843)k; basic EPS $0.03; Adjusted EBITDA $8,044k vs $(5,580)ksec.gov — Condensed Consolidated Statements of Operations and the Second Quarter Financial Results table, Form 8-K Exhibit 99.1 filed 2026-07-30
- Derived growth rates and margins, Q2 2026derived2026-06-30Revenue +21.56% YoY; Diagnostics +19.64%; Data & applications +27.97%; GAAP gross margin 64.45%; GAAP operating margin -19.85%; Adjusted EBITDA margin 2.10%sec.gov — 382,486/314,635-1 = 21.56%; 289,333/241,843-1 = 19.64%; 93,153/72,792-1 = 27.97%; 246,498/382,486 = 64.45%; -75,913/382,486 = -19.85%; 8,044/382,486 = 2.10%. Company rounds revenue growth to 22%.
- Composition of GAAP net incomefiled2026-06-30Net income $5,642k includes $102,757k of 'other income, net' (of which $98.5M unrealized gains on marketable securities per the release highlights), $(11,643)k loss on debt extinguishment, $(10,283)k interest expense and $3,897k interest income; also absorbed $55.6M of stock compensation and related employer payroll taxessec.gov — Second Quarter 2026 Summary Results bullet and the Condensed Consolidated Statements of Operations. Without the securities gain the quarter is loss-making at every level.
- Non-GAAP gross margin reconciliationfiled2026-06-30Q2 2026 non-GAAP gross profit $251,279k, non-GAAP gross margin 65.7% (GAAP 64.4%) vs 62.8% / 62.0% in Q2 2025. Segment: Diagnostics GAAP GM 62.6% (58.8% prior year), Data & applications GAAP GM 70.2% (72.7% prior year)sec.gov — Reconciliation of GAAP to Non-GAAP Financial Measures tables in the release
- Balance sheet at 2026-06-30filed2026-06-30Cash & equivalents $599,614k; marketable equity securities $216,377k; restricted cash $4,724k; total assets $2,365,911k; convertible senior notes, net $1,172,781k; convertible promissory note $187,929k; revolving credit facility $0 (was $100,000k); long-term debt, net $0 (was $202,753k); interest payable $19,155k; total liabilities $1,920,977k; goodwill $470,166k; intangibles net $312,457ksec.gov — Condensed Consolidated Balance Sheets. Derived net debt: (1,172,781 + 187,929) - (599,614 + 216,377) = $544,719k.
- H1 2026 cash flow, capex and derived free cash flowderived2026-06-30Net cash used in operating activities $(80,802)k (vs $(61,460)k H1 2025); purchases of property and equipment $(14,327)k; capitalized software costs $(6,832)k; derived FCF $(101,961)k = -14.0% of H1 revenue; capex intensity 2.9%sec.gov — OCF and investing lines are filed. FCF derived: -80,802 - 14,327 - 6,832 = -101,961; margin -101,961/730,602 = -13.95%. Capex intensity (14,327+6,832)/730,602 = 2.90%.
- H1 2026 revenue and operating lossfiled2026-06-30Total net revenue $730,602k vs $570,372k (+28.1% derived); loss from operations $(160,624)k vs $(130,463)k; Diagnostics $550,431k; Data & applications $180,171k; SG&A $438,439ksec.gov — Six-month columns of the Condensed Consolidated Statements of Operations; H1 growth rate derived: 730,602/570,372-1 = 28.10%
- FY2026 guidancefiled2026-07-30Revenue raised to $1.595-1.605B (~25% annual growth); Adjusted EBITDA unchanged at ~$65M; guidance assumes no impact from the Personalis transactionsec.gov — 'Financial Outlook and Guidance' section. Derived implication: H1 Adjusted EBITDA was ~$5.2M (Q1 $(2.8)M + Q2 $8.0M), so ~$59M of the ~$65M target falls in H2.
- Operating and strategic metricsfiled2026-06-30Oncology volume +31% YoY (from +28% prior quarter); MRD volume 9,000 tests (from 6,500); Insights revenue +36%; ~$200M of new Data and Applications licences signed; FDA approval of tumor-only xT CDx enabling ADLT pricing; first oncology foundation model delivered to AstraZeneca; $460M 0.0% convertible senior notes due 2032 completedsec.gov — Second Quarter 2026 Highlights and Recent Operational Highlights in the release
- Personalis acquisition termsfiled2026-07-20Definitive agreement to acquire Personalis at $16.25 per share, ~$1.5 billion enterprise value; NeXT Personal ultrasensitive tumor-informed MRD; announced 2026-07-20; expected to close late Q4 2026 or early 2027sec.gov — Disclosed in the Q2 2026 earnings release (Recent Operational Highlights). Separate 8-Ks were filed 2026-07-20 but were not retrieved in this refresh.
- Share price and market capmarket2026-08-03 (close)$46.05 close on 2026-08-03 (+4.97% that day); market cap $8.31B; 180.43M shares outstanding; 52-week range $40.77-$104.32stockanalysis.com — Closing price, not intraday. Cross-check: 46.05 x 180.43M = $8.31B, consistent with the quoted market cap. Down ~23.9% from the $60.52 close in the prior 2026-07-06 vintage.
- 10-Q for the same periodfiled2026-06-30Form 10-Q for the quarter ended 2026-06-30, filed 2026-07-30sec.gov — The filing that triggered this refresh (filingSignal: 10-Q filed 2026-07-30). Figures above are taken from the 8-K Exhibit 99.1 earnings release accompanying it.
The thesis on this name
State of AI for Healthcare
The largest listed pure-play in the cohort at $7.92B — before the pending all-stock Personalis acquisition, which will raise the share count behind that cap and the fastest grower at +50.4%, and it rides none of the surviving shift-points: the revenue line that carries it is reimbursed genomic testing, where the payer is CMS's fee schedule and the commercial payer's contract — the two payers this board finds do not fund software margin.
Earnings, margins, COGS & capex
Revenue reached $1.27B in FY2025 (+83.4%, lifted by the Ambry Genetics deal) and $348.1M in Q1 2026 (+36.1%), split between Diagnostics (~75% of revenue) and the higher-value Data & Applications business (~25%). Gross margin sits in the low-to-mid 60s%. The company remains GAAP-unprofitable (FY2025 net loss $(245.0)M) but Adjusted EBITDA has swung sharply toward breakeven - from roughly $(104.7)M in FY2024 to $(7.4)M in FY2025 (with Q4 2025 positive at $12.9M) - and management guides FY2026 to positive ~$65M Adjusted EBITDA, the first full-year positive-EBITDA target.
Income statement — where each revenue dollar goes
% of revenueOf every $1 of revenue, ~36¢ is cost of goods and ~64¢ operating expense, and the remainder is an operating loss.
Revenue trend
Margins
improving from 60.7% a year earlier; gross profit outpacing revenue
stable/up
up (gross profit growing faster than revenue)
improved ~$97M YoY (from ~$(104.7)M); Q4 2025 positive at $12.9M
improved from $(16.2)M YoY
loss narrowing relative to revenue
COGS structure
Diagnostics COGS is dominated by sequencing reagents/consumables, lab labor, instrument depreciation, and specimen logistics - the driver of the ~35-37% cost of revenue. Data & Applications carries much lower incremental cost (data already captured), so segment mix shift toward Data is the structural gross-margin lever. Non-GAAP gross margin (65%) strips stock-comp and acquisition-related amortization.
Capex
Capital goes to sequencing capacity, lab automation/build-out, and capitalized internal-use software/AI platform; supplemented by M&A (Ambry Genetics, Paige AI, OneOme) rather than organic-only capex. Not disclosed as a standalone headline metric here.
Latest earnings
Mixed, and the stock slipped. Revenue $382.5M (+21.6%) with first-ever positive GAAP net income of $5.6M and positive Adjusted EBITDA of $8.0M; FY2026 revenue guidance was raised to $1.595-1.605B. But the raise's $1.600B midpoint sits modestly below the ~$1.61B street figure, top-line growth decelerated from +36.1% in Q1 to +21.6%, Hereditary revenue grew only 5%, and the GAAP profit is entirely non-operating — $98.5M of unrealized gains on marketable securities against a loss from operations that widened to $(75.9)M from $(61.8)M.
FY2026 revenue raised to $1.595-1.605B (~25% annual growth). FY2026 Adjusted EBITDA UNCHANGED at ~$65M. Guidance explicitly assumes NO impact from the Personalis transaction, which is expected to close in late Q4 2026 or early 2027.
- Oncology testing volume
- +31% YoY, accelerating from +28% in Q1 2026
- MRD volume
- 9,000 tests in Q2 2026, up from 6,500 in Q1 2026 (+38% sequentially)
- Data Licensing & Modeling (Insights)
- Revenue +36% YoY; total Data & Applications $93.2M (+28.0%)
- New Data & Applications bookings
- ~$200M signed in the quarter (BioNTech, Daiichi Sankyo, Level Set Bio, Incyte)
- Diagnostics revenue
- $289.3M (+19.6%), with Hereditary revenue up only 5% offsetting the 31% oncology volume growth
- Adjusted EBITDA
- $8,044k vs $(5,580)k in Q2 2025 — a $13.6M YoY improvement, 2.1% margin
- Cash and marketable securities
- $820.7M at 2026-06-30, against $1.36B of convertible debt
- Regulatory / product
- FDA approval of tumor-only xT CDx (migrates tissue testing to ADLT pricing); first lab with CDx approval for both tumor-only and tumor-normal CGP; first oncology foundation model delivered to AstraZeneca
- Capital structure action
- Completed $460M of 0.0% coupon convertible senior notes due 2032; repaid $207.7M term loan and $100M revolver — Q2 interest expense halved to $10.3M from $21.6M
- Personalis acquisition
- Definitive agreement announced 2026-07-20 at $16.25/share, ~$1.5B enterprise value; tumor-informed NeXT Personal MRD; closes late Q4 2026 or early 2027
Growth drivers
- Oncology testing volume - +28% YoY in Q1 2026, the core reimbursed-test engine
- MRD (minimal residual disease) ramp — ~6,500 tests in Q1 2026, up ~500% YoY, a large TAM adjacent to Natera/Guardant
- Data & Applications - +40.5% YoY in Q1 2026, the high-margin pharma-data licensing engine
- Hereditary testing - +54% volume YoY in Q1 2026 (Ambry Genetics)
- Pharma collaborations — multi-year strategic Merck deal for biomarker discovery; expanding book of biopharma data contracts
- Menu + modality expansion beyond oncology (cardiology, hereditary via Ambry, algorithmic/AI diagnostics via Paige AI)
Reported financials — SEC EDGAR
Audited GAAP figures pulled from SEC filings · latest filing 2026-02-24. The audited primary-source spine — not financial advice.
Revenue — annual (GAAP)
Margins & balance sheet — FY’25
Bull & bear
The unit economics finally crossed over: Q2 delivered the company's first positive GAAP net income and a second consecutive positive Adjusted EBITDA quarter, gross margin expanded 240bps to 64.4%, and the non-GAAP operating loss narrowed 84% to just $(2.7)M. Underneath, the two highest-value engines accelerated — oncology volume +31% and Insights revenue +36% — while the FDA's tumor-only xT CDx approval unlocks ADLT pricing and the 0% convertible refinancing halved interest expense.
- First positive GAAP net income ($5.6M) and Adjusted EBITDA of $8.0M vs $(5.6)M a year ago — a $13.6M YoY swing, with non-GAAP loss from operations down 84% to $(2.7)M
- Gross margin 64.4% GAAP / 65.7% non-GAAP, up from 62.0% / 62.8%; gross profit grew 26% against 21.6% revenue growth, so mix and scale are both working
- Oncology testing volume +31% YoY, ACCELERATING from +28% in Q1 — the core reimbursed engine is speeding up, not slowing
- MRD ramp is steep and sequential: 9,000 tests in Q2 from 6,500 in Q1 (+38% QoQ), attacking the Natera/Guardant TAM
- Data & Applications $93.2M (+28%) with Insights +36% and ~$200M of new licences signed in one quarter (BioNTech, Daiichi Sankyo, Level Set Bio, Incyte) — the high-margin, low-incremental-cost engine
- Diagnostics gross margin expanded 380bps to 62.6% — the lab is getting more efficient per test as volume scales
- FDA approval of the tumor-only xT CDx makes Tempus the first laboratory holding CDx approval for both tumor-only and tumor-normal comprehensive genomic profiling, and migrates tissue testing to ADLT pricing
- Delivered the first version of an oncology foundation model to AstraZeneca — the data library converting into model-licensing revenue rather than just data access
- Capital structure materially improved: $460M of 0.0% coupon converts due 2032 retired a $207.7M term loan and $100M revolver; Q2 interest expense fell to $10.3M from $21.6M
- Personalis (~$1.5B EV, $16.25/share) consolidates the tumor-informed MRD franchise with a partner whose technology Tempus is already commercialising
Growth halved and the profit is a mark. Revenue growth decelerated from +36.1% in Q1 to +21.6% in Q2, Hereditary grew 5%, and the celebrated GAAP net income of $5.6M exists only because of $98.5M of unrealized gains on marketable securities — the actual loss from operations WIDENED to $(75.9)M. Cash burn worsened, FY Adjusted EBITDA guidance was left unchanged at ~$65M (implying a heavily back-loaded H2), and ~$545M of net convertible debt sits ahead of a ~$1.5B acquisition.
- Deceleration is the headline number that matters: total revenue +21.6% YoY in Q2 vs +36.1% in Q1 2026; Diagnostics +19.6% vs +34.7% in Q1; Hereditary revenue +5% after +54% volume growth the prior quarter — the Ambry contribution has lapped and stalled
- GAAP net income of $5.6M is entirely non-operating: $102.8M of 'other income, net' including $98.5M of UNREALIZED gains on marketable equity securities, against a loss from operations of $(75,913)k that got $14.1M WORSE than the $(61,774)k a year earlier
- The same line cuts the other way and recently did: Q1 2026 carried a $32.3M unrealized LOSS on the same $216.4M securities book. This is a volatility engine bolted onto the P&L, not earnings
- Adjusted EBITDA of $8.0M is a 2.1% margin, and FY2026 Adjusted EBITDA guidance was left UNCHANGED at ~$65M while revenue guidance rose — H1 delivered roughly $5M, so ~$59M must come in H2, a steep back-half load
- Cash burn is worsening, not narrowing: H1 operating cash flow $(80,802)k vs $(61,460)k a year ago; H1 free cash flow $(101,961)k after capex and capitalized software
- Leverage is real and growing: $1,360,710k of convertible debt (senior notes $1,172,781k + promissory note $187,929k) against $815,991k of cash and marketable equity securities = ~$545M net debt; total liabilities $1,920,977k on $2,365,911k of assets
- Data & Applications gross margin FELL to 70.2% from 72.7% — the structural margin lever is itself compressing
- SG&A of $225,845k is 59% of revenue and grew 25% YoY, faster than the 21.6% revenue growth; total cost and operating expenses grew 21.8%, so the operating-loss gap is not closing on GAAP terms
- The guidance raise's $1.600B midpoint sits below the ~$1.61B street figure — a raise that is functionally a trim relative to expectations
- Personalis adds ~$1.5B of enterprise value (at $16.25/share) for an unprofitable MRD asset, closing late Q4 2026 or early 2027 and explicitly EXCLUDED from guidance, so the financing mix, dilution, and integration cost are all unpriced
- Price action confirms the skepticism: $46.05 (2026-08-03) is ~23% below our prior 2026-07-06 vintage and ~56% below the $104.32 52-week high
- $11.6M loss on debt extinguishment in Q2 is the cash cost of the refinancing that produced the interest saving — the benefit is real but was paid for
What it is worth
Price/sales on forward revenue (typical for high-growth, not-yet-GAAP-profitable diagnostics/data names) cross-checked against EV vs. FY2026 guidance and peer multiples (GH, NTRA, EXAS)
Organic deceleration, a reimbursement or regulatory shock, continued GAAP losses/dilution, or competitive share loss compresses the multiple toward the ~$7-8B lower end seen at the 52-week low (~$42/sh).
~$10-11B
mid-single-digit forward P/S on ~25% total growth reaching positive EBITDA; valuation tracks execution on MRD ramp and pharma-data renewals.
Sustained ~35% growth with Data-mix-driven gross-margin expansion and Adjusted EBITDA scaling well past the ~$65M FY2026 target justifies a premium P/S and re-rating toward the upper end of its 52-week range.
At ~$10.82B market cap on ~$1.59-1.60B FY2026 guided revenue, TEM trades ~6.8x forward sales - a premium reflecting the data moat and EBITDA inflection, but on a business still GAAP-loss-making. Multiple is highly sensitive to organic-growth durability (post-Ambry ~25%) and reimbursement. Not financial advice.
SWOT
Strengths
- Proprietary multimodal dataset (clinical + molecular + imaging) at scale - the durable asset rivals can't easily replicate
- Dual revenue engine: reimbursed diagnostics feed a high-margin pharma data/insights business
- High growth (+36.1% Q1 2026) with gross margin expanding into the mid-60s%
- Deep pharma relationships (multi-year Merck collaboration; broad biopharma contract book)
- Founder-led (Eric Lefkofsky) with strong capital access and an M&A playbook (Ambry, Paige AI, OneOme)
Weaknesses
- Still GAAP-unprofitable — FY2025 net loss $(245.0)M; positive Adjusted EBITDA relies on non-GAAP add-backs (heavy stock-comp)
- Diagnostics revenue depends on third-party reimbursement rates (CMS/payers) it does not control
- Growth flattered by acquisitions (Ambry) - organic growth is lower than the headline 83% FY2025 figure
- Heavy stock-based compensation dilutes shareholders ($56.3M SBC + payroll tax in Q1 2026 alone)
- Capital intensity of lab operations caps the leverage a pure-software peer would enjoy
Opportunities
- MRD/recurrence monitoring - a multibillion-dollar TAM where Tempus is scaling from a small base
- Expansion beyond oncology into cardiology, neuropsych, and hereditary testing
- AI/algorithmic diagnostics (Paige AI) and drug-discovery data partnerships as generative-AI demand for clinical data rises
- Cross-sell data licensing against its growing installed test base
- International expansion of both diagnostics and data licensing
Threats
- Intense, well-capitalized competition (Guardant, Natera, Foundation Medicine/Roche, Exact Sciences, Caris)
- Reimbursement/coverage cuts or LDT/FDA regulatory changes to lab-developed tests
- Patent litigation (active IP disputes, incl. with Guardant Health)
- Data-privacy/HIPAA and consent regime risk on the de-identified data business
- Valuation risk — a high-multiple, not-yet-GAAP-profitable name is sensitive to rate/sentiment swings and any growth deceleration
Moats, dependencies & bottlenecks
Moats
Proprietary multimodal data library (clinical + molecular + imaging) at scale Hardest asset to replicate; grows with every test and underpins the pharma data business and AI models
Data/diagnostics flywheel (tests generate data that is re-monetized) Self-reinforcing scale advantage; weakens only if reimbursement pressure shrinks the test engine
Multi-year contracts and workflow integration create switching costs; contestable by Flatiron/IQVIA/ConcertAI
Regulatory/clinical validation + payer coverage for its test menu Coverage and validated assays are a barrier, but also a dependency on external payers/regulators
Patents exist but are actively litigated (e.g., Guardant), so not uncontested
Dependencies
Revenue / regulatory Diagnostics revenue realization depends on coverage decisions and per-test rates outside Tempus's control
Core lab consumables concentrate on a few vendors; pricing/supply affects COGS
Customer concentration Data & Applications growth leans on a book of large biopharma contracts; renewals matter
Not yet GAAP self-funding; relies on cash reserves and market access, with ongoing dilution
Changes to lab-developed-test oversight or data-consent rules could raise costs or constrain the data business
Advantages
- Largest-in-class linked clinical-molecular oncology dataset
- Only major peer running both a diagnostics engine and a data-licensing engine at scale
- Rapid MRD growth into a large adjacent TAM
- Founder-led capital access and M&A capability
- Cross-sell leverage: installed test base seeds data-product demand
Weaknesses
- GAAP losses and reliance on non-GAAP EBITDA framing
- Acquisition-dependent headline growth masking slower organic growth
- Payer-reimbursement dependency on the core diagnostics revenue
- High share-based compensation and dilution
- Premium valuation vulnerable to any growth/margin disappointment
Bottlenecks
- Path to GAAP profitability while funding growth and heavy stock-comp
- Reimbursement rate ceilings on diagnostics limiting per-test economics
- Scaling lab/sequencing capacity and turnaround time as volumes grow
- Sales cycle and concentration risk in landing/renewing large pharma data contracts
- Integrating acquisitions (Ambry, Paige AI, OneOme) without margin drag
Top signals & trends
Top signals
Momentum plus first positive full-year EBITDA target
Third-party validation of the data asset; supports Data & Applications growth
Traction in a large new category, though off a small base
Organic deceleration once Ambry laps out
Profitability rests on non-GAAP add-backs; dilution continues (though ~$32M of the Q1 loss was non-cash unrealized securities losses)
High volatility/valuation sensitivity for a not-yet-profitable growth name
Trends
Directly benefits the Data & Applications business
Expands the reimbursed-test TAM Tempus serves
Large adjacent market; also intensely contested by Natera/Guardant
Could raise compliance costs or constrain data monetization
Caps per-test economics for the diagnostics engine
Ecosystem & competitor graph
Suppliers feed the company; customers pull from it. Line thickness shows the strength of each tie (supply-chain dependency, customer earnings contribution). Hover to isolate a tie.
Primary NGS sequencing platforms and reagents underpinning the diagnostics COGS base
Lab instruments, reagents, and consumables
Compute and storage for the multimodal data platform and AI models
Cloud compute and storage for the data platform
Alternative long-read sequencing supplier in the ecosystem
Multi-year strategic biomarker-discovery collaboration; flagship pharma data customer
License Tempus's de-identified multimodal data and Insights products for drug development
Order reimbursed diagnostic tests (oncology NGS, hereditary, MRD, cardiology)
Reimburse the diagnostic tests - economic gatekeeper for Diagnostics revenue
Direct rival in liquid biopsy/ctDNA and MRD; active patent litigation with Tempus
MRD (Signatera) leader and oncology/hereditary molecular testing - head-to-head in Tempus's fastest-growing category
Broad cancer diagnostics/screening (Cologuard, Oncotype) and MRD entrant; peer in molecular-test economics
Comprehensive genomic profiling + companion diagnostics with deep pharma ties; core CGP competitor (owned by Roche, not separately listed)
Molecular profiling + AI/data play closely analogous to Tempus's model; IPO'd on Nasdaq June 2025
Oncology testing lab services competitor
Scale reference-lab incumbent expanding in oncology/advanced diagnostics
Large reference lab with oncology and companion-diagnostics reach
Leading real-world oncology data/EHR platform - direct competitor to the Data & Applications business (owned by Roche, not separately listed)
Health-data and real-world-evidence giant competing for pharma data spend
Private oncology real-world-data + AI competitor to Data & Applications (no public ticker)